Iboga comes from the rainforests of Central Africa and has been used in Bwiti initiation for generations. Ayahuasca is a brewed combination of two Amazonian plants used across dozens of indigenous traditions in South America. Both address trauma, addiction, and depression — through different mechanisms, at different durations, with different demands on the person taking them. Neither is a substitute for the other.
The short answer:Iboga is a root bark from Gabon used in multi-day Bwiti ceremony — active for 12–24 hours with a 2–3 day recovery period. Ayahuasca is a brewed tea from the Amazon — active for 4–6 hours, typically taken over one or several nights. Iboga works primarily through ibogaine's action on opioid, dopamine, and serotonin receptors and produces extensive autobiographical material. Ayahuasca works primarily through DMT's serotonergic action and produces visionary states that are less narrative in content. The right choice, if either is appropriate, depends on what you are working with — not on which sounds more manageable.
What Iboga Is
Tabernanthe iboga is a shrub native to the rainforests of Gabon, Cameroon, and the Republic of Congo. The root bark contains more than 30 alkaloids, the most studied of which is ibogaine. For centuries it has been used in the Bwiti tradition — a complex of spiritual practice centred on initiation, ancestral connection, and the confrontation of what practitioners call the deep self.
In a traditional Bwiti initiation, iboga root bark is consumed over multiple days. The experience is understood not as therapy but as a passage — a formal encounter with the medicine that changes a person's relationship to themselves and their community. The ceremony is typically a one-time event in the traditional context, though some people work with iboga multiple times.
In contemporary ceremonial contexts outside Gabon, whole root bark is used alongside or instead of extracted ibogaine. The full plant is considered by many practitioners to produce a different quality of experience than the isolated alkaloid — more grounded, less acute, with the contribution of the full alkaloid profile rather than ibogaine alone. Iboga ceremony at ExploreBwiti uses whole root bark in the Bwiti tradition.
The pharmacological action of ibogaine is unusual. It acts on opioid, dopamine, NMDA, sigma, and nicotinic receptors simultaneously. It is a long-acting compound — the active period runs 12–24 hours, and its primary metabolite, noribogaine, remains active in the body for weeks to months afterward. This extended metabolite presence is thought to be part of why iboga's effects on addiction and mood persist well past the ceremony itself.
What Ayahuasca Is
Ayahuasca is a brewed combination of two plants: Banisteriopsis caapi, a vine containing monoamine oxidase inhibitors (MAOIs), and Psychotria viridis (or equivalent DMT-containing plants), whose primary psychoactive compound, DMT, is otherwise broken down by the body before it reaches the brain. The MAOI in the vine allows the DMT to become orally active.
Ayahuasca has roots in dozens of indigenous traditions across the Amazon basin — Shipibo-Conibo, Shuar, Achuar, Santo Daime among them — each with distinct ceremonial forms, plant preparations, and cosmologies. The brew is typically drunk in ceremony over one night, with sessions repeating over several days in some traditions. The active period runs approximately 4–6 hours.
The experiential quality of ayahuasca is primarily visionary. People commonly encounter geometric and figurative imagery, archetypal presences, and states that feel cosmological in scale. The experience tends to be less autobiographical than iboga — less concerned with the personal history — though insights into personal patterns do emerge.
How They Differ
The differences between iboga and ayahuasca are significant enough that the comparison "which is better" usually reflects a misunderstanding of what each does.
- Duration: Iboga is active for 12–24 hours, with a 2–3 day recovery period. Ayahuasca is active for approximately 4–6 hours, with most people functional within a day.
- Mechanism:Iboga is multi-receptor — opioid, dopamine, serotonin, NMDA, sigma. Ayahuasca is primarily serotonergic, through DMT's action on 5-HT2A receptors.
- Content of experience: Iboga tends to produce extensive autobiographical material — people revisit specific memories, relive relational patterns, and encounter what they have been avoiding about their own history. Ayahuasca tends to produce visionary content that is more symbolic and less personal, though this varies by individual and tradition.
- Physical demand: Iboga is more physically demanding. Nausea, vomiting, and ataxia are common. The cardiac burden is real — ibogaine prolongs the QT interval, which is why cardiac screening is required before iboga ceremony and not optional. Ayahuasca is also physically purging for many people, but the cardiovascular risk profile is different.
- Tradition: Iboga is rooted in a specific geographic tradition (Bwiti, Central Africa). Ayahuasca spans dozens of traditions across South America with significant variation in ceremony structure, plant preparation, and cosmology.
- Persistence of effects:Ibogaine's metabolite (noribogaine) remains active for weeks to months. DMT has a half-life of minutes — its effects after ayahuasca clear in hours.
What Each Works With Clinically
The clinical evidence for iboga centres on opioid use disorder, treatment-resistant depression, PTSD, and addiction broadly. The Stanford study published in Nature Medicine in February 2023 documented an 88% reduction in PTSD symptoms, 87% reduction in depression symptoms, and 81% reduction in anxiety symptoms at one month post-treatment, in a cohort of 30 special operations veterans who had not responded to conventional care. To put that in context: conventional antidepressant research considers a 50% reduction in depression scores a strong response. These are not typical outcomes.
The people who arrive at iboga ceremony with the strongest results are often the ones who spent years trying everything else first. SSRIs that blunted rather than resolved. Therapy that circled without landing. Abstinence-based programmes that held for months, then didn't. By the time they arrive, they have evidence that other approaches are not enough — and that scepticism, earned the hard way, tends to produce people who are genuinely ready to encounter what iboga shows them.
Ayahuasca has a separate body of clinical literature centred on depression, trauma, and substance use disorders, primarily from research groups in Brazil, Spain, and Canada. A growing number of PubMed-indexed studies document significant antidepressant effects, with some showing rapid-onset response similar in timing to ketamine. The evidence base is smaller and younger than iboga's clinical record, but the direction is consistent.
The practical difference: iboga's opioid receptor activity makes it particularly relevant for opioid dependence — ayahuasca does not have the same mechanism and is not used for acute opioid withdrawal. For trauma and depression without addiction, the two medicines address similar territory through different paths.
Using Both in Sequence
Some people work with both medicines — not in the same ceremony, but over time. The most common sequence is iboga first, ayahuasca later. There are practical reasons for this.
Iboga's autobiographical quality — the tendency to surface specific memories, relational patterns, and what the person has been avoiding — creates a detailed map of what needs integration. The material is concrete and personal. Ayahuasca's more visionary and symbolic register can then work with the same terrain from a different angle, offering archetypal or cosmological perspective on what iboga surfaced at the personal level.
The pharmacological constraint is important: combining psychedelics requires careful spacing. Because ayahuasca contains MAOIs, there is a required clearance period after iboga before ayahuasca work can be considered. The MAOI content of ayahuasca interacts with the serotonergic system in ways that require the iboga compounds to have cleared — a question best answered by the medical professionals involved in each ceremony, not by a general article.
Working with both medicines is not a standard protocol. It is something some people do over years, with multiple integration periods in between, not as a compressed treatment sequence. Anyone considering both should be working with providers who communicate clearly with each other about the person's history, medication profile, and readiness.
What Neither Medicine Does
Iboga is not a cure for addiction. Neither is ayahuasca. Both can open a window — a period of reduced craving, increased neuroplasticity, and greater access to the patterns that produced the problem. What happens during that window determines the outcome. Ceremony followed by a return to the same environment, relationships, and unaddressed conditions produces the same results. The integration period is not a bonus service — it is where the ceremony's work is either applied or lost.
Neither medicine is a shortcut to insight. Both tend to deliver what a person needs rather than what they hoped for, and those are often not the same thing. People who arrive primarily seeking a profound or spiritual experience frequently leave having encountered exactly what they have been avoiding — which is the point, and is also not what they imagined.
Who Should Not Work With Ayahuasca
Ayahuasca contains MAOIs. Anyone currently taking SSRIs or SNRIs — or who has recently tapered off them — faces a serious risk of serotonin syndrome, which can be fatal. This is not a preference or a precaution: it is an absolute contraindication. The combination of MAOI-containing ayahuasca with serotonergic medications creates a physiological risk that has killed people. There are no exceptions to this rule.
Ayahuasca is also contraindicated for people with active psychosis, schizophrenia spectrum disorders, or first-degree family history of schizophrenia. DMT's action on the serotonergic system can precipitate or worsen psychotic episodes. Screening exists because it is not always obvious from self-report who is at risk.
Pregnancy is an absolute contraindication for ayahuasca. Other contraindications vary by the specific plant preparation and the individual's medication and health history — a complete medication review is required before any ayahuasca ceremony with a serious provider.
Who Should Not Work With Iboga
Iboga's cardiac profile requires more screening than ayahuasca's. Ibogaine prolongs the QT interval — a measure of cardiac electrical activity. In people with pre-existing QT prolongation, significant cardiac arrhythmia, or recent myocardial infarction, this can produce fatal arrhythmia. Any ibogaine provider who skips cardiac screening is not operating safely. EKG and cardiovascular assessment are not optional add-ons — they are the difference between a ceremony and a fatality. The cardiac deaths that have occurred in ibogaine contexts are concentrated among providers who omitted this step.
The absolute contraindications for iboga ceremony are:
- QT prolongation, significant cardiac arrhythmia, or recent myocardial infarction
- Severe liver or kidney disease (ibogaine is hepatically metabolised)
- Active psychosis or schizophrenia spectrum disorder
- Current SSRIs or SNRIs — a supervised taper is required before iboga ceremony is considered, with sufficient washout time for full clearance
- Methadone — a specific transition protocol is required; people on methadone are not simply screened in or out, they require a tailored approach
- Lithium and certain other psychiatric medications that interact with ibogaine's cardiac and neurological effects
- Pregnancy
These are not preferences. They are the conditions under which iboga ceremony produces serious risk of death or permanent harm. The full contraindications list for iboga covers additional medications and conditions that require evaluation before a decision is made. Medical screening for iboga ceremony at ExploreBwiti requires an EKG, full blood panel, cardiovascular assessment, complete medication review, and psychiatric history — before any ceremony is scheduled.
Someone in acute psychiatric crisis is not an appropriate candidate for either medicine — regardless of how urgently they feel they need it. The experience amplifies what is present. Entering either ceremony in a state of acute instability does not produce stability.
Is Either Right for You?
The question of which medicine — if either — is appropriate depends on what you are working with, your medical history, your medication history, and your capacity for what either ceremony involves. It is not a question answered by an article. It is answered through a screening conversation with people who know both medicines well.
If you are working with opioid dependence, treatment-resistant depression, or PTSD that has not responded to conventional approaches, the iboga ceremony page describes what the screening process involves and what to expect. If you have questions about whether your medications or medical history are disqualifying, the FAQ covers the most common questions in detail. If you have done prior plant medicine work and are considering how iboga fits into that picture, the ibogaine vs ayahuasca comparison covers the pharmacological differences in more depth.
If none of the contraindications apply and you want to start a conversation, you can reach us at jake.nylund@gmail.com. We respond within 2–3 business days with a personal reply. We will tell you directly if what you are describing does not make you an appropriate candidate.